ArticleOncology letters2025
Multimodal treatment for multifocal metastatic maxillary adenoid cystic carcinoma: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maxillary adenoid cystic carcinoma (ACC) is rare, with pleural and brain metastases representing an unprecedented presentation. The present case report illustrates the challenges and potential for prolonged survival in such an advanced stage of malignant disease. A 52-year-old male patient presented with a left maxillary mass, initially misdiagnosed as ameloblastoma; subsequently, it was confirmed as maxillary ACC (T4aN0M0, stage IVA). Following primary tumor resection and radiotherapy, the patient developed pleural (February 2021) and brain metastases (March 2022). A multimodal treatment strategy was used, involving aggressive surgical resection of the primary tumor, comprehensive radiotherapy, systemic chemotherapy regimens and adjuvant targeted molecular therapy. By using this sequential multimodal therapy, the patient achieved long-term survival exceeding 5 years. The present case report highlights the potential for favorable, prolonged survival even in the presence of multifocal metastatic maxillary ACC when managed with a persistent, sequential and tailored combination of modern therapeutic modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.